Amgen (NASDAQ:AMGN) Earns “Neutral” Rating from Cantor Fitzgerald
Cantor Fitzgerald reissued their neutral rating on shares of Amgen (NASDAQ:AMGN – Free Report) in a research report released on Tuesday,Benzinga reports. Cantor Fitzgerald currently has a $305.00 target price on the medical research company’s stock. AMGN has been the topic of several other research reports. Guggenheim initiated coverage on Amgen in a report on […]
Cantor Fitzgerald reissued their neutral rating on shares of Amgen (NASDAQ:AMGN – Free Report) in a research report released on Tuesday,Benzinga reports. Cantor Fitzgerald currently has a $305.00 target price on the medical research company’s stock. AMGN has been the topic of several other research reports. Guggenheim initiated coverage on Amgen in a report on […]
